Quidel's CEO Presents At Canaccord Genuity 32nd Annual Growth Conference (Transcript)

Quidel Corp. (QDEL)

Canaccord Genuity 32nd Annual Growth Conference Transcript

August 14, 2012 10:00 AM ET

Executives

Doug Bryant - President and CEO

Randy Steward - Chief Financial Officer

Ruben Argueta - Investor Relations

Analysts

Jeff Frelick - Canaccord Genuity

Presentation

Jeff Frelick - Canaccord Genuity

Compare to:
Previous Statements by QDEL
» Quidel's CEO Discusses Q2 2012 Results - Earnings Call Transcript
» Quidel's CEO Presents at Goldman Sachs Healthcare Conference (Transcript)
» Quidel's CEO Discusses Q1 2012 Results - Earnings Call Transcript
» Quidel's CEO Discusses Q4 2011 Results - Earnings Call Transcript

Joining us today from Quidel we have Doug Bryant, we have Randy Steward, CFO; and Ruben Argueta, IR. So please join us across the room for breakout, immediately following the presentation.

As you know, Quidel is a leading point-of-care company. I think those again to a robust new product cycle that the company is embarking on. I’ll point you to book -- conference manuals for disclose statements.

And with that, I’d like to turn it over to Doug.

Doug Bryant

Thanks, Jeff, and good morning. We will be making forward-looking statements. This particular slide gets [denser] of how I think we present. Quidel is a company that’s very well-positioned and where it has become a fairly attractive diagnostic market space, in particular the area we focus in point-of-care and recently in molecular, those two areas are actually the fasted growing in that segment.

We have a fairly significant product pipeline that addresses a number of different market opportunities. We are known as an infectious disease company. So, clearly, we have products in development in that space, but we are also interested in the women’s health category and we have a number of products in development there.

Increasing commercial footprint, recently in U.S. we doubled our sales organization and those guys, at the moment are engaged in launching our newest product Sofia. I’ll talk more about that in a second. And finally, it is a company that has a healthy balance sheet, good revenues and very little debt.

1 2 3 Next › Last »